Buzzberg Cup Bracket locked

Rebound signal for pharma/bio? The real deal will be decided in July

Rebound signal for pharma/bio? The real deal will be decided in July | Myeong Min-jun, Park Ga-young, Park Ji-hoon [Stock Beginner Rescue Team]
Watch on YouTube ↗  |  June 26, 2026 at 13:30  |  51:34  |  3PRO TV (삼프로TV)
Speakers
Park Ji-hoon — Director, Asset Management Consulting Dept., NH Investment & Securities

Summary

Park Ji-hoon, Manager at NH Investment & Securities, analyzes a market dominated by leveraged ETF concentration that is suppressing non-semiconductor sectors. He sees a rotation signal when leveraged ETF volume drops, and identifies specific opportunities in undervalued Samsung Electronics, KOSDAQ Active ETFs, Korean biotech (DND Pharmatech, Hanall Biopharma, Alteogen, Olix), Samsung Electro-Mechanics, and a bottoming second battery sector in July.

  • Leveraged ETF daily trading volume at 15 trillion won is overwhelming non-semiconductor stocks; a drop below 10 trillion would trigger a rebound in victim sectors.
  • Samsung Electronics is considered undervalued vs. SK Hynix based on HBM4 potential, foundry turnaround, and stronger shareholder return tools.
  • The new KOSDAQ premium index will attract passive funds, favoring KOSDAQ Active ETFs and select premium-grade stocks like Alteogen.
  • US biotech ETFs are strong while Korean biotech has been decimated; a July rebound is possible if Samsung earnings merely meet consensus.
  • DND Pharmatech has high deal expectations in July; Hanall Biopharma is cheap relative to its rallying US partner Immunovant.
  • Samsung Electro-Mechanics deserves renewed attention as Q2 earnings begin to benefit from April price hikes.
  • The second battery down cycle is ending with consensus upgrades for LG Energy Solution and Samsung SDI; July is viewed as a bottom.
  • Margin call levels have spiked to crisis-era levels, but the speaker warns against leverage rather than issuing a market-wide call.
Ideas
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment & Securities 28:20
KOSDAQ Active ETF benefits from upgrade system
The upcoming KOSDAQ premium index, launched under the new upgrade system, will attract passive fund inflows into selected premium-tier stocks. A KOSDAQ Active ETF strategy can capture this, as these ETFs will likely hold the premium-grade names, driving both trading volume and price appreciation.
KOSDAQ Active ETF MED
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment & Securities 34:00
Samsung Electronics undervalued vs SK Hynix
Samsung Electronics is undervalued relative to SK Hynix. The market is giving too high a multiple to SK Hynix despite Samsung's upcoming HBM4 leadership, potential foundry turnaround in Q3, and stronger shareholder return policy tools. Historically, when SK Hynix market cap briefly surpassed Samsung, the market corrected. Samsung should trade at a premium, and its expected Q2 operating profit (potentially reaching 100 trillion won if beat) could ignite a rally.
005930.KS HIGH
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment & Securities 35:36
Non-semiconductor rebound when leveraged ETF volume drops
When daily trading volume of leveraged ETFs drops below 10 trillion won, the ‘victim stocks’ (non-semiconductor, heavily sold-off names) will finally rebound. Currently at 15 trillion, this massive concentration suppresses all other sectors. Monitoring this volume threshold provides the timing signal for a broader market rotation out of semiconductors.
KOSDAQ Index MED
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment & Securities 37:14
Korean biotech/pharma sector to rebound in July
US biotech ETFs (XBI, IBB) are performing well while Korean biotech/pharma has been crushed. A sector rebound can come in July if Samsung Electronics’ Q2 earnings merely meet consensus (not blow out), allowing rotational flows. Institutions are already buying select names ahead of catalysts like Kolon TissueGene phase 3 results.
Korean Biotech/Pharma Sector MED
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment & Securities 39:40
DND Pharmatech deal expectations in July
DND Pharmatech has high expectations for a deal announcement in July, with strong market anticipation driving institutional interest. The stock is among the key biotech names positioned for a catalyst-driven rebound.
347850.KQ MED
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment & Securities 39:51
Hanall Biopharma gap to partner to close
Hanall Biopharma’s US partner Immunovant is rallying strongly, but Hanall’s stock price has diverged and lagged. This gap should close as the market recognizes the value of their collaboration, making Hanall a trusted biotech pick.
009420.KQ MED
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment & Securities 40:12
Alteogen premium index inclusion and royalties
Alteogen is highly likely to be included in the new KOSDAQ premium index, which will bring passive flows. Additionally, its royalty revenue stream from now to 2030 is unquestioned, giving it a solid fundamental base as a KOSDAQ leader.
196170.KQ MED
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment & Securities 40:36
Olix leading mRNA trend play
Olix is consistently recognized as a leading player in the mRNA trend, making it one of the favored biotech picks amid the sector’s expected recovery and continued research & development theme.
226950.KQ MED
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment & Securities 47:30
2nd battery down cycle ending, July bottom
The secondary battery down cycle is ending. LG Energy Solution and Samsung SDI are seeing their earnings consensus revised upward. July is viewed as a potential bottom, making this a good accumulation window for the cell makers ahead of a cycle recovery.
373220.KS 006400.KS MED
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment & Securities 50:08
Samsung Electro-Mechanics Q2 earnings improving
Samsung Electro-Mechanics has been neglected lately but deserves renewed attention. Its Q2 earnings will start to improve significantly as price hikes from April begin to be reflected, kicking off a new earnings upturn cycle.
009150.KS MED
Up Next
8:12
Billionaire investor Jeremy Grantham: This is the most expensive market in American history
CNBC · Jun 26
1:43:07
ANDRÉ JAKURSKI: LIÇÕES IMPERDÍVEIS DE QUASE 50 ANOS DE MERCADO | Market Makers #380
Market Makers · Jun 26
5:03
What the Street is saying now about SpaceX two weeks out from its IPO
CNBC · Jun 26
1:04:29
Too Early to Get Off the Wave | TCAF 248
The Compound News · Jun 26
11:21
Will Gamers Ignore GTA VI’s Hefty $80 Price Tag?
Bloomberg Markets · Jun 26

This 3PRO TV (삼프로TV) video, published June 26, 2026, features Park Ji-hoon discussing KOSDAQ Active ETF, 005930.KS, KOSDAQ Index, Korean Biotech/Pharma Sector, 347850.KQ, 009420.KQ, 196170.KQ, 226950.KQ, 373220.KS, 006400.KS, 009150.KS. 10 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Park Ji-hoon  · Tickers: KOSDAQ Active ETF, 005930.KS, KOSDAQ Index, Korean Biotech/Pharma Sector, 347850.KQ, 009420.KQ, 196170.KQ, 226950.KQ, 373220.KS, 006400.KS, 009150.KS